CJ Bioscience, Inc. (KOSDAQ:311690)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,360
-90 (-0.79%)
Last updated: Mar 25, 2025
-30.56%
Market Cap 136.66B
Revenue (ttm) 3.47B
Net Income (ttm) -32.84B
Shares Out 13.07M
EPS (ttm) -3,541.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,749
Average Volume 98,051
Open 11,450
Previous Close 11,450
Day's Range 11,320 - 11,570
52-Week Range 8,250 - 18,800
Beta 0.86
RSI 42.57
Earnings Date Mar 20, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 311690
Full Company Profile

Financial Performance

In 2024, CJ Bioscience's revenue was 3.47 billion, a decrease of -37.82% compared to the previous year's 5.58 billion. Losses were -32.84 billion, 43.3% more than in 2023.

Financial Statements

News

There is no news available yet.